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Abstract 
Objective: Cyclooxygenase-2 (COX-2), one of the rate-limiting enzymes in the metabolism 
of arachidonic acid which is reported to be involved in the pathogenesis of many human 
tumors. As well, Vascular endothelial growth factor (VEGF) is well known to be involved in 
the infiltration and metastasis of many kinds of cancers. The aim of this study was to further 
elucidate  the  clinicopathologic  significance  of  the  immunohistochemical  expressions  of 
COX-2 and VEGF in thyroid carcinoma.  
Methods: Eighty-five patients with thyroid neoplasms were enrolled in our study from 
December 2003 to January 2010 from the authors' institution retrospectively. Their tumors 
were examined in the Department of Pathology, the First Bethune Hospital of Jilin University. 
Immunohistochemistry was performed on paraffin-embedded tissues sections using mono-
clonal anti-human COX-2 and VEGF antibodies. The tissues were classified into four types: 
papillary, follicular, medullary and undifferentiated. The patients ranged in age from 23 to 71 
years. Breast cancer slides acted as control slides. The immunohistochemical stains were 
quantified by staining intensity and by the proportion of positively stained cells which were 
stained brown or yellow. 
Results: The results were analysed by 
2 test. COX-2 and VEGF expressions were stronger 
in thyroid carcinoma than in thyroid adenomas and normal tissues (P<0.01). COX-2 and VEGF 
expressions in thyroid carcinoma correlated with the tumor type and TNM stage. 
Conclusion: Our results suggest that expression of COX-2 and VEGF may promote angi-
ogenesis of thyroid carcinoma, its infiltration, and metastasis. 
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Introduction 
Cyclooxygenases (COX), components of the ar-
achidonic acid cascade are a family of catalyzing en-
zymes that convert cellular arachidonic acid to pros-
taglandin.  There  are  two  major  cyclooxygenases, 
COX-1  and  COX-21. COX-1  is  a  housekeeping  gene 
that is expressed constitutively in a variety of human 
tissues. COX-2 is an inducible gene2. Recently it has 
been reported that COX-2 is overexpressed in many 
human tumors, including colorectal carcinoma, gas-
tric carcinoma, gallbladder carcinoma and liver can-
cer3-6. This observation has suggested that COX-2 may 
play a critical role in the carcinogenesis and progres-
sion  of  tumors.  Many  researchs  have  demonstrated 
that COX-2 is not only responsible for cell prolifera-
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tion and transformation, but also for inducing angio-
genesis7,8. However, the mechanism is unclear.  
Thyroid  carcinoma  is  one  of  the  common  ma-
lignant human tumors. Its prognosis correlates with 
its pathological type. The prognosis of papillary car-
cinoma  being  the  best,  followed  by  follicular  carci-
noma  and  medullary  carcinoma9.  The  prognosis  of 
undifferentiated carcinoma is worst with a high mor-
tality rate10. It is well known that angiogenesis plays 
an  important  role  in  the  growth  and  metastasis  of 
thyroid carcinoma4. Thyroid carcinoma cells can po-
tentially secrete many provascular factors to promote 
angiogenesis.  To  date,  vascular  endothelial  growth 
factor (VEGF) appears to be the most important an-
giogenic factor, and may be responsible for the infil-
tration and metastasis of thyroid carcinoma11,12. But 
the  mechanism  that  regulats  its  overexpression  in 
tumor cells is unclear. In this study we investigated 
the expression of COX-2 and VEGF in thyroid carci-
noma,  and  then  analyzed  their  correlation  and  the 
relationship between them and the pathological type 
and TNM stage.  
Materials and methods 
Patient enrollment 
The study protocol was approved by the ethics 
committee at the First Bethune Hospital of Jilin Uni-
versity. Following the Institutional Guideline for in-
formed  consent  in  our  hospital,  Paraffin-embedded 
tissue samples were obtained from the Department of 
Pathology  at  the  First  Hospital  of  Jilin  University. 
There were 35 male and 50 female patients, ranging in 
age from 23 to 71 years. The specimens included 10 
normal thyroid tissues, 15 thyroid adenomas, and 60 
thyroid carcinomas. According to the WHO classifi-
cation criteria13, there were 28 papillary carcinomas, 
10  follicular  carcinomas,  12  medullary  carcinomas, 
and  10  undifferentiated  carcinomas.  According  to 
TNM  (International  Union  Against  Cancer,  UICC) 
criteria, there were 19 stage I tumors, 23 stage II tu-
mors, 8 stage III tumors and 10 stage IV tumors. None 
of the patients had been treated with radiotherapy or 
chemotherapy  before  surgery.  All  samples  were 
re-examined  by  hematoxylin-eosin  staining  and  di-
agnosis confirmed on the basis of it. The clinical rec-
ords of all patients were reviewed to determine pa-
tients follow-up status and lymph node metastasis of 
thyroid carcinoma statistically, which referred to the 
postoperative  pathology  of  dissected  lymph  nodes 
around tumors. 
Antibody 
SABC (Strept Avidin-Biotin Complex) immuno-
histochemical  method  and  rabbit  anti-human  poly-
clonal  antibodies  to  COX-2(3F7)  and  VEGF-A(SP21) 
were  purchased  from  Fuzhou  Maxin  Biotechnical 
Company (Fuzhou, China). They were employed at a 
dilution 1:50 which was the proper concentration for 
the best results. 
Immunohistochemistry  
SABC  immunohistochemical  method  was  used 
to  detect  the  expression  of  COX-2  and  VEGF.  The 
formalin-fixed  tissues  were  embedded  in  paraffin, 
and sectioned at a thickness of 4μm. The sections were 
deparaffinized and hydrated gradually. Sections were 
heated  in  a  microwave  oven  for  15  min  to  retrieve 
antigens.  The  sections  were  incubated  with 
non-immune goat serum for 15 min at room temper-
ature to eliminate non-specific staining. The sections 
were  then  incubated  with  the  primary  antibody 
against COX-2 and VEGF (dilution 1:50) for 60 min at 
room temperature, washed three times with PBS for 
5min, and incubated with the secondary antibody for 
15  min  followed  by  avidin-biotin-peroxidase  for  15 
min  at  room  temperature.  Finally,  the  slides  were 
washed three times for 15 min with PBS, visualized 
with DAB reagent, and counterstained with haema-
toxylin.  Negative  and  positive  controls  were  used 
simultaneously to ensure specificity and reliability of 
the staining process. The negative controls were ob-
tained by using PBS instead of the primary antibody. 
Some  studies  have  reported  that  COX-2  is  overex-
pressed in breast cancer. So we chose breast cancer 
sections as positive controls14,15. 
Immunohistochemical evaluation 
Sections were observed under a light microscope 
after  having  been  mounted.  Positive  staining  with 
COX-2 and VEGF were defined as brown staining in 
the  cytoplasm  or  nuclei.  According  to  Kawasaki’s 
method16, the antigen expression was  quantified on 
the basis of staining intensity and the proportion of 
positively stained cells. The staining intensity of posi-
tive cells was graded as 0, 1, 2, 3. On the basis of the 
proportion of positive cells, slides were classified as 0 
(0%), 1 (1-25%), 2 (26-50%), 3 (51-75%), 4 (76-100%). 
An  overall  staining  score  was  determined  by  the 
product of these two grades: 0, ≤3, 3－6 and ≥6 were 
defined as negative (-), positive(+), moderate positive 
(++), and strong positive (+++). (For each slice, five 
regions were evaluated at a magnification of 100. An 
average score was determined to avoid random sam-
pling.) 
Statistical analysis 
All  statistical  analysis  were  carried  out  with Int. J. Med. Sci. 2012, 9 
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SPSS software version 10.0. The relationship between 
COX-2  expression  and  categorical  variables  was 
compared  by  the  2  test  or  Fisher  two-sided  exact 
probability test. Continuous variables were analyzed 
with student t test. A P value <0.05 was considered to 
be  statistically  significant.  Correlation  analysis  was 
performed by the Spearman method. 
Results 
Expression of COX-2 and VEGF protein in 
thyroid cancer tissues 
Yellow  or  brown  granules  could  be  seen  dif-
fusely in the cytoplasm of COX-2 positive cells (Fig. 
1).  Tumor  cells  and  vascular  endothelial  cells  with 
diffuse brown granules were defined as VEGF posi-
tive cells (Fig. 2). No stained granules could be seen in 
normal thyroid tissues. The expressions of COX-2 and 
VEGF  in  thyroid  carcinomas  were  higher  than  in 
thyroid adenomas (P<0.01). The expression of COX-2 
and  VEGF  in  undifferentiated  carcinoma  was  most 
strong and greater than in papillary or follicular car-
cinomas. The positive rate correlated with the TNM 
stage and lymph node metastasis (Table 1). 
 
 
 
Fig 1: normal thyroid tissue, COX-2(-)VEGF(-), original magnifi-
cation x200. 
 
Table 1. Relationship between the expression of COX-2 and VEGF and parameters of clinical pathology in thyroid cancer. 
Group  n  COX-2    VEGF 
+  －  2  P  +  －  2  P 
Normal thyroid  10  0  0        0  0     
Thyroid adenoma  15  2(13)  13(87)  12.054  0.001a    6(40)  9(60)  6.756  0.009e 
Thyroid cancer  60  38( 63)  22(37)    45(75)  15(25) 
Tissue type 
Papillary type  28  10(36)  18(64)  11.951  0.008b    16(57)  12(43)  9.056  0.029f 
Follicular type  10  7(70)  3(30)    5(50)  5(50) 
Medullary type  12  9 (75)  3 (25)    10(83)  2(17) 
Undifferentiated type  10  9(90)  1(10)    10(100)  0(0) 
TNM stage 
Ⅰ~Ⅱ  42  21(50.  21(50)  8.061  0.005c    27(64)  15(36)  5.860  0.015g 
Ⅲ~Ⅳ  18  16(89)  2(11)    17(95)  1(5) 
Lymphatic metastasis 
Yes  23  19(83)  4(17)  6.920  0.009d    22(96)  1(4)  5.840  0.020h 
No  37  18(49)  19(51)    24(65)  13(34) 
COX-2: 
a;Thyroid adenoma vs Thyroid cancer: 2=12.054, P=0.001; 
b:Papillary type vs Follicular type vs Medullary type vs Undifferentiated type: 2=11.951, P=0.008; 
c;Stage I-II vs Stage III-IV: 2=8.061, P=0.005; 
d:Lymphatic metastasis vs No lymphatic metastasis: 2=6.920, P=0.009; 
VEGF: 
e:Thyroid adenoma vs Thyroid cancer: 2=6.756, P=0.009; 
f:Papillary type vs Follicular type vs Medullary type vs Undifferentiated type: 2=9.056, P=0.029; 
g:Stage I-II vs Stage III-IV: 2=5.860, P=0.015; 
h:Lymphatic metastasis vs No lymphatic metastasis: 2=5.840, P=0.020. 
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Fig 2: Thyroid papillary cancer, COX-2 (+++), original magnifi-
cation x200. 
 
 
 
Fig 3: Thyroid papillary cancer, VEGF (++), original magnification 
x200. 
 
Correlation between COX-2 and VEGF ex-
pressions in thyroid cancer tissues 
Among  the  38  COX-2  positive  cases,  36  cases 
were  associated  with  positive  VEGF  staining.  The 
positive  rate  of  VEGF  in  the  COX-2  positive  group 
was  much  higher  than  that  in  the  COX-2  negative 
group. Among 15 VEGF negative cases, 13 cases pre-
sented with negative COX-2 staining. The difference 
between the two groups was statistically significant. 
COX-2  and  VEGF  expression  demonstrated  a  ten-
dency  towards  having  a  positive  correlation  with  a 
correlation coefficient of 0.59 (P<0.01) determined by 
the Spearman method (Table 2). 
Discussion 
It  has  been  documented  that  COX-2  plays  an 
important role in the development of human tumors 
and  suggested  that  COX-2  may  promote  the  tumor 
growth and invasion17-19. Recent research has found 
that COX-2 can be detected in many human tumors 
and may be overexpressed in tumor tissues compared 
with  normal  tissues.  Uefuji  et  al20  investigated  the 
expression of COX-2 in 23 cases of gastric adenocar-
cinoma, and found in 19 cases (83%) that COX-2 ex-
pression  was  positive  by  immunohistochemical 
staining. In addition, Eberhart21 examined 14 cases of 
human  colon  cancer  and  found  increased  levels  of 
COX-2 mRNA in 12 cases (86%). In colonic adenomas 
the expression rate of COX-2 mRNA was 43% (6/14). 
Tucker  et  al22  discovered  that  the  level  of  COX-2 
mRNA in pancreatic cancer was 60 times more than in 
adjacent  cancerous  tissues.  Molina  et  al5  found 
COX-2mRNA amplification in 21 cases of pancreatic 
cancer.  Among  them,  in  67%  cancer  tissues  COX-2 
immunohistochemistry  staining  was  positive.  This 
observation suggest that overexpression of COX-2 is a 
characteristic of malignant tumors. 
 
 
Table 2. Relationship between the expression of COX-2 
and VEGF in thyroid cancer. 
VEGF  
 
 
COX-2 
－  +－++  +++ 
— 
 
13
# 
 
1 
 
1 
 
+－++ 
 
6  12  3 
+++  3  5  16
* 
#P<0.01 compared with COX-2(+++);*P<0.01 compared with 
COX-2(-); r=0.636. 
 
 
 
To  the  best  of  our  knowledge,  only  a  small 
number of studies have examined COX-2 expression 
in thyroid carcinoma23. However, their research did 
not  investigate  possible  correlation  between  COX-2 
and VEGF. Their conclusions about the clinicopatho-
logic correlation of COX-2 expression in thyroid car-
cinoma remain controversial. In this study, we found 
that the expression of COX-2 and VEGF were much 
higher in thyroid carcinomas than in thyroid adeno-
mas and normal thyroid tissues. Especially, their ex-
pression in thyroid cancer correlated with the patho-
logic type, clinical period  and tumor stage. The ex-
pressions  of  COX-2  and  VEGF  in  undifferentiated 
carcinomas  and  medullary  carcinomas  were  higher 
than  in  papillary  and  follicular  carcinoma,  and  the Int. J. Med. Sci. 2012, 9 
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differences were significant statistically (P<0.01). It is 
known that compared with papillary carcinoma the 
prognosis of undifferentiated carcinoma and medul-
lary  carcinoma  is  worse10.  Our  data  confirm  that 
overexpression  of  COX-2  correlates  with  the  patho-
logic  type  of  thyroid  carcinoma,  and  suggest  that 
COX-2  overexpression  is  associated  with  a  poor 
prognosis.  In  addition,the  expression  of  COX-2  in 
thyroid  adenomas  was  higher  than  that  in  normal 
tissues. These findings suggest that overexpression of 
COX-2 may be an early event in the progression of 
thyroid neoplasms. 
It  is  recognized  that  the  growth  of  tumors  re-
quires adequate blood to supply nutrition and oxy-
gen.  Consequently,  the  ability  of  tumors  to  induce 
angiogenesis  is  very  important  for  the  tumor 
growth24-26.  Tsujii  et  al27  have  demonstrated  that 
COX-2  may  promote  carcinogenesis  by  a  paracrine 
mechanism.  They  co-cultured  endothelial  cells  and 
colon  cancer  cell,and  discovered  that  COX-2  could 
induce the colon cancer cells to release vasculogenic 
prostaglandin which promoted endothelial migration 
and angiogenesis. This process could be inhibited by 
aspirin, NS-398 (a selective inhibitor of COX-2), and 
antibodies to provascular factors. Uefuji et al20 inves-
tigated the expression of COX-2 in 42 cases of primary 
gastric  adenocarcinoma.  They  found  microvessel 
density  in  tissues  overexpressing  COX-2  was  much 
higher than that in tissues with low COX-2 expression 
(P<0.01).  Animal  experiments  have  also  confirmed 
that the selective COX-2 inhibitor Celecoxib can in-
hibit angiogenesis of transplanted rat lung and colon 
tumors2.  Hence,  a  further  investigation  is  required 
regarding  the  clinical  use  of  COX-2  inhibitors  as  a 
possible  therapeutic  strategy  for  thyroid  carcinoma, 
especially tumors with a strong expression of COX-2. 
On  the  basis  of  these  studies,  we  suggest  that  the 
mechanism  by  which  COX-2  induces  angiogenesis 
correlates with the expression of provascular factors. 
In our study, VEGF was also overexpressed in all 
types of thyroid carcinoma, and it correlated with the 
degree of differentiation and tumor stage. It has also 
been demonstrated that VEGF plays a critical role in 
the pathogenesis of thyroid cancer. Fu et al28 found 
that COX-2 inhibitors restrained tumor angiogenesis, 
and  downregulated  the  expression  of  VEGF.  This 
suggested that COX-2 overexpression was probably 
one  of  initiation  mechanisms  for  VEGF  overexpres-
sion.  In  our  study,  we  detected  co-expression  of 
COX-2 and VEGF in thyroid cancer. COX-2 and VEGF 
may together be involved in the progression of thy-
roid cancer. We performed correlation analysis of the 
expression of COX-2 and VEGF in thyroid cancer, and 
found COX-2 and VEGF expression presented a posi-
tive correlation. This suggests that COX-2 and VEGF 
interact  in  the  pathogenesis  of  thyroid  cancer.  It  is 
suggested that COX-2 may be involved in the tran-
scriptional regulation of VEGF gene. This study pro-
vides further understanding of the molecular mecha-
nism of thyroid carcinogenesis and adds experimental 
evidence for a relationship between COX-2 expression 
and carcinogenesis. 
In  summary,  there  was  a  positive  correlation 
between COX-2 and VEGF expressions. This provided 
further weight to the suggestion to the motion that 
COX-2 may promote carcinogenesis by inducing an-
giogenesis29. This is consistent with previous research 
results. It suggests that an antisense DNA technique 
or COX-2 inhibitors might interfere with the expres-
sion of COX-2 or inhibit its activity to restrain the ex-
pression of VEGF and inhibit carcinogenesis30,31.  
Conclusion 
In our study, we found that COX-2 and VEGF 
expression in thyroid cancer was higher than in be-
nign thyroid adenomas and normal thyroid tissues. In 
addition, our research shows there is a positive cor-
relation between COX-2 and VEGF expressions. This 
indicates that COX-2 may promote carcinogenesis by 
inducing angiogenesis. This is consistent with previ-
ous  research  results.  It  suggests  that  an  antisense 
DNA technique or COX-2 inhibitors might interfere 
with the expression of COX-2 or inhibit its activity to 
silence expression of VEGF and inhibit carcinogene-
sis. Hence, as an early event of carcinogenesis, COX-2 
might be a potential gene therapy target, worthy of 
further research. 
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